Mansfield Center, CT, United States of America

Michael Pikal

USPTO Granted Patents = 11 


 

Average Co-Inventor Count = 5.9

ph-index = 6

Forward Citations = 175(Granted Patents)


Company Filing History:


Years Active: 2003-2021

Loading Chart...
Loading Chart...
Loading Chart...
11 patents (USPTO):Explore Patents

Title: The Innovations of Michael Pikal

Introduction

Michael Pikal, a prominent inventor based in Mansfield Center, CT, has made significant contributions to the field of pharmaceutical formulations. With a total of 11 patents to his name, Pikal's work has focused on enhancing the stability and efficacy of Factor VIII compositions, which are crucial for the treatment of hemophilia.

Latest Patents

Among his most noteworthy inventions are his recent patents related to Factor VIII formulations. These formulations are designed to minimize or completely eliminate NaCl in the final product, resulting in a reduction of the lyophilization cycle time. This innovation leads to increased stability of the lyophilized Factor VIII, making it a vital advancement in the field of biopharmaceuticals.

Career Highlights

Throughout his career, Michael Pikal has collaborated with renowned institutions and companies, including the University of Connecticut and Baxalta GmbH. His extensive experience in the pharmaceutical industry, coupled with his inventive mindset, has positioned him as a key player in the development of improved therapeutic formulations.

Collaborations

Pikal has worked closely with various professionals in his field, including notable colleagues such as Marc Besman and Erik Bjornson. Their collaborations have likely contributed to the success of his innovations and the advancement of treatments available for patients requiring Factor VIII.

Conclusion

Michael Pikal's innovative contributions to Factor VIII formulations illustrate the powerful impact of dedicated inventors in the pharmaceutical realm. His continued efforts and recent patents not only enhance the stability of essential treatments but also pave the way for future advancements in biopharmaceutical technology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…